Member Info for Mer400

I doubt very much they promised anything.

Doesn't really matter what the share price is.

2 things have changed in the last 6-12 month

1 people who were optimistic changed their minds.

2 CPX has signed more deals to secure a better future for the company.

End of June

Did cape not say the license fee issue should be sorted by now?

You might be right but if you don't have the ability to manufacture large quantities then you don't really have much choice its a means to an end.

Will you put half your pay in the pot to help out?

What news?

Would be good if they managed to source others means of funding.

You gotta ask why they binned 2 legal teams. what are the possible scenarios for this? the only reason I can think of is they thought you weren't going to win so advised to settle. you wouldn't get rid of someone that thought you were going to win.

Am I missing something? so we may need to raise further funds to see us through to profitability.which isn't to bad considering the last 2 year. The mcap is now 22 million from 90 million a few months ago, Russia is obviously kicking off but patients need treating whether there's a war or not.

Did anyone attend the investor evening.

The easy explanation is you read it wrong. They did not say they will need funding in the next few months. they said

The impact of this on Efmody® sales and the extent of further financing for the Company to reach profitability will be assessed over the coming months.

Mitchell Kapoor

Hi, everyone. Thank you for taking the questions today. The first one is regarding ALKINDI SPRINKLE, could you just comment on any barriers to uptake you're seeing, if you are seeing any?

Sean Brynjelsen

No, this is Sean. Thanks for the question. The ALKINDI SPRINKLE numbers are looking great. I'm very happy with the partnership with Tolmar. We just had a record week of new prescriptions last week and we've seen that week over week, so it's not a -- I believe it's a good trend. It's a positive trend, I don't want to get too -- I don't want to overstate it. But right now, we are feeling very optimistic about our ALKINDI numbers, our ability to hit our goals and to hit a significant number of patients this year. So that's some -- that's where we're at. If there are -- there are some barriers, doctors and patients are working through those. Some -- just like for example, barrier might be somebody who's used to using the compounded product and you give them something that's different. They have to get used to that. They have to understand it, learn about it. And that whole process can take some time. Some people it happens quick. Some people it happens not so quick. But we're starting to see the doctors prescribe it. And there's also a shortage of compounded hydrocortisone from what I understand, which is perhaps also hoping to good win for us.

Are they not buying capx through murata and this contract is set up for when that license agreement ends

I doubt they's sign a contract for 5 units?

Th uk government does a similar thing for r&d. it’s an incentive for companies to develop new technolgy and encourage new companies.

I don't think Guys is sexist at all, I use it to address a group of people regardless of gender I have female friends who do the same and they do it to their female friends. Maybe it once was in the Guys n Gal's days but not now.

The last interim results stated.

Total Sales Revenue of A$2.1 million (2019: A$1.9 million) up 10%.

then the chairmans last statement said.

Despite the impact on manning and production our Q1 sales have again been strong, up 25% on the same period last year.

If that trend continued into the second quarter the 2.1m + 25% = 2.625m. up 525k. We had a loss last year of 400k.
if that trend continues for the rest of the year which I see no reason why it shouldn't as new customers come on board we should hit profit

2 trading days left before results. Might see some movement.

This time next week rodders!!